Liu Jian, Zhu Qian, Li Yun, Qiao Guo-Liang, Xu Chang, Guo De-Liang, Tang Jie, Duan Rui
Department of general surgery, Jingmen First People's hospital, 67 Xiangshan avenue, 448000 Jingmen, Hubei Province, China.
Department of general surgery, Jingmen First People's hospital, 67 Xiangshan avenue, 448000 Jingmen, Hubei Province, China.
Clin Res Hepatol Gastroenterol. 2018 Sep;42(4):330-338. doi: 10.1016/j.clinre.2018.02.003. Epub 2018 Mar 16.
We aimed to identify the independent predictive factors of microvascular invasion (MVI) for curative resection of HCC and to investigate the impacts of MVI and HBeAg on long-term recurrence and survival after resection.
The clinicopathological parameters of 237 patients with HCC with MVI who underwent hepatic resection from April 2005 to November 2010 were investigated. Clinical features and factors associated with the clinical outcomes of 386 patients with HCC without MVI were used for comparison.
Multivariate stepwise logistic regression analysis revealed that alpha-fetoprotein level>100μg/L, positive HBeAg, and tumour size were independent prognostic factors in patients with HCC with MVI. The overall survival (OS) of patients in the HCC with MVI group was significantly poorer compared with the HCC without MVI group (P<0.001). However, patients with HCC without MVI group exhibited a significantly better recurrence-free survival rate (RFS) (P<0.001). While the HCC with positive HBeAg group exhibited significantly lower OS compared with the HCC with negative HBeAg group (P=0.007).
AFP level>100μg/L, positive HBeAg, and tumour size>2cm are independent indicators of poorer prognosis for HCC with MVI. The present study confirmed that microvascular invasion itself had a negative impact on patient survival; moreover, HBeAg was an independent risk factor influencing OS, while not RFS of patients with HCC underwent hepatectomy. It is important to predict the presence of MVI before hepatic resection to determine treatment strategies.
我们旨在确定肝细胞癌(HCC)根治性切除术中微血管侵犯(MVI)的独立预测因素,并研究MVI和乙肝e抗原(HBeAg)对切除术后长期复发和生存的影响。
对2005年4月至2010年11月期间接受肝切除的237例伴有MVI的HCC患者的临床病理参数进行了研究。将386例无MVI的HCC患者的临床特征和与临床结局相关的因素用于比较。
多因素逐步逻辑回归分析显示,甲胎蛋白水平>100μg/L、HBeAg阳性和肿瘤大小是伴有MVI的HCC患者的独立预后因素。伴有MVI的HCC组患者的总生存期(OS)明显低于无MVI的HCC组(P<0.001)。然而,无MVI的HCC组患者的无复发生存率(RFS)明显更好(P<0.001)。HBeAg阳性的HCC组患者的OS明显低于HBeAg阴性的HCC组(P=0.007)。
AFP水平>100μg/L、HBeAg阳性和肿瘤大小>2cm是伴有MVI的HCC预后较差的独立指标。本研究证实,微血管侵犯本身对患者生存有负面影响;此外,HBeAg是影响接受肝切除术的HCC患者OS而非RFS的独立危险因素。在肝切除术前预测MVI的存在对于确定治疗策略很重要。